Central retinal artery occlusion after Moderna mRNA-1273 vaccination

Central retinal artery occlusion after Moderna mRNA-1273 vaccination

Bibliographic Details
Main Authors:	Sin Yu Chow, Yung-Ray Hsu, Vai Hong Fong
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Series:	Journal of the Formosan Medical Association
Online Access:	http://www.sciencedirect.com/science/article/pii/S092966462200256X

Similar Items

Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination
by: Tyng-Shiuan Hsieh, et al.
Published: (2023-01-01)

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
by: Angel Shabu, et al.
Published: (2023-12-01)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
by: Leelakrishna Channa, BS, et al.
Published: (2021-09-01)

Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship?
by: Gerardo Cazzato, et al.
Published: (2023-03-01)

Guillain‐Barré syndrome after mRNA‐1273 (Moderna) COVID‐19 vaccination: A case report
by: Zauraiz Anjum, et al.
Published: (2022-04-01)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
by: Suresh Babu Chellapandian, et al.
Published: (2022-04-01)

Central Retinal Vein Occlusion after mRNA COVID-19 Vaccination
by: Kiyona Ishiguro, et al.
Published: (2023-05-01)

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
by: Masahiro Iwata, et al.
Published: (2023-04-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
by: Nazmul Islam, et al.
Published: (2022-05-01)

Antibody response to the messenger RNA‐1273 vaccine (Moderna) in liver transplant recipients
by: Antonio Cuadrado, et al.
Published: (2022-07-01)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
by: Oleguer Parés-Badell, et al.
Published: (2022-07-01)

Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
by: Sammy Patyna, et al.
Published: (2022-04-01)

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine
by: Abdulbaril Olagunju MD, et al.
Published: (2022-04-01)

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters
by: Bethany Girard, et al.
Published: (2024-03-01)

Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine
by: Yoji Hoshina, et al.
Published: (2022-07-01)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
by: Szu-Ting Huang, et al.
Published: (2023-11-01)

mRNA-1273 is placenta-permeable and immunogenic in the fetus
by: Jeng-Chang Chen, et al.
Published: (2025-03-01)

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
by: Maria De Santis, et al.
Published: (2022-05-01)

Longitudinal extensive transverse myelitis after COVID-19 vaccination (Spikevax mRNA-1273, Moderna) in a patient with rheumatoid arthritis
by: Saemi Choi, et al.
Published: (2022-12-01)

Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech
by: Dulat Bekbolsynov, et al.
Published: (2024-01-01)

Suboptimal humoral immunological response to the 2nd dose of anti-COVID19 mRNA-1273 vaccine (Moderna) in kidney transplant patients
by: Jesús Martín-García, et al.
Published: (2023-05-01)

Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
by: Angel Shabu, et al.
Published: (2023-12-01)

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination
by: Sun Hye Shin, et al.
Published: (2022-01-01)

Comment on: Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination
by: Pradeep K Panigrahi
Published: (2022-01-01)

Central retinal artery occlusion
by: Sohan Singh Hayreh
Published: (2018-01-01)

Antibodies against SARS-CoV-2 Alpha, Beta, and Gamma Variants in Pregnant Women and Their Neonates under Antenatal Vaccination with Moderna (mRNA-1273) Vaccine
by: Wei-Chun Chen, et al.
Published: (2022-08-01)

Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
by: Takayuki Yamada
Published: (2023-05-01)

Immunostimulatory/Immunodynamic model of mRNA‐1273 to guide pediatric vaccine dose selection
by: Vijay Ivaturi, et al.
Published: (2025-01-01)

Acute Generalized Exanthematous Pustulosis in Close Temporal Association with mRNA-1273 Vaccine
by: Fouad Mitri, et al.
Published: (2021-11-01)

Delayed Skin Reactions to COVID-19 mRNA-1273 Vaccine: Case Report and Literature Review
by: Ruei-Lin Wang, et al.
Published: (2022-08-01)

Combined central retinal vein occlusion and branch retinal artery occlusion
by: Sugandha Goel, et al.
Published: (2018-01-01)

Combined central retinal artery occlusion and vein occlusion with exudative retinal detachment following COVID‐19 vaccination
by: Yen‐Chih Chen
Published: (2022-10-01)

Subcutaneous panniculitis‐like T‐cell lymphoma post‐mRNA‐1273 COVID‐19 vaccination
by: Sho Ukishima, et al.
Published: (2023-04-01)

Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine
by: Lucrezia Mencarelli, et al.
Published: (2023-08-01)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
by: Anna Giuliano, et al.
Published: (2023-07-01)

Tracking B cell responses to the SARS-CoV-2 mRNA-1273 vaccine
by: Felipe Lopes de Assis, et al.
Published: (2023-07-01)

Update on central retinal artery occlusion
by: Ramesh Venkatesh, et al.
Published: (2024-06-01)

Sustained S-IgG and S-IgA antibodies to Moderna’s mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations
by: Jennifer Serwanga, et al.
Published: (2024-01-01)

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
by: Elif Karatas, MD, et al.
Published: (2023-02-01)